Covid vaccine: It needs to be gain, not harm


2020 has been a difficult year, with the emergence of Covid-19disrupting the world 's original process, many lives remaining forever in 2020, and as survivors we seem to have finally seen a little light, thanks to the great efforts and efforts of scientists and pharmaceutical companies, many vaccines have been introduced, which is encouraging, and the Buddha is a little light at the end of a long dark tunnel.  But we also need to be vigilant and cautious, and fast-delivering vaccines remain fraught with risks, the most important of which is the risks associated with the safety of the vaccine itself.

The safety of the mRNA vaccine still needs to be evaluated

On March 2, nursing staff at a nursing home in Berlin, Germany, reported that 25 percent of the residents of a nursing home with dementia had died immediately after receiving the Pfizer vaccine, and36 percent of the residents had suffered serious injuries or even near death in a short period of time.  Norway, on the other part of the country, has confirmed as many as 29 deaths over the age of 75 since vaccination began on December 27 last year.  In a written response to Bloomberg on January 16, the Norwegian Drug Administration said that until the 15th, the vaccine produced by Pfizer-BioNTech SE was the only vaccine in Norway, so "all deaths are related to this vaccine".

In December, Dr. J. Patrick Whelan   expressed concern that the new mRNA vaccine technology used by Pfizer and Modern in the United States "may cause microvascular damage (inflammation and small blood clots called micro thrombosis) to the brain, heart, liver, and kidneys in a way that is not evaluated in the safety trial evaluation."  The Mr. NA vaccine used by the two companies actually tells human cells to make a protein that triggers an immune response that protects people from infection if a real virus enters the body.   But the new technology has not yet been shown to be safe in large-scale use, and the current spread of the vaccine is actually a process of directly testing humans on a large scale. There are also immunologists who say that, unlike inactivated vaccines, large-scale use of mRNA vaccines has a risk of causing abnormal immune dysfunction, allergies and even death, especially in the elderly and people with underlying diseases.

Many adverse vaccine reactions or deaths that occur in different countries and regions should alarm governments about the need to choose and procure vaccines with greater care, such as inactivated vaccines with more sophisticated technologies, or to buy vaccines produced by manufacturers in different countries, rather than the high-risk approach of putting all eggs in one basket, as in Norway.

The European vaccine has been called into question

Official reports of allergic reactions are rare as the government rushes to introduce a vaccine to contain a global pandemic. But the AstraZeneca vaccine, produced by a Swedish-British joint venture of biopharmaceutical companies, has actually been a problem since its launch, and there has been resistance in many countries.

The effectiveness of The AstraZeneca vaccine is in doubt.     


AstraZeneca initially disclosed the data in the wrong way and a series of irregularities and omissions, and late last year, Astronautic announced that its vaccine was 62 percent effective after two full-dose trials, but 90 percent after half-dose and full-dose trials, which British regulators now say is 70 percent effective, while the European Medicines Agency says 60percent, and that vague differences in efficacy undermine public confidence in vaccine reliability.Industry experts also say the vaccine is poorly transparent and rigorous. Last month, South Africa announced it was shut down for questioning its effectiveness.South Africa's health minister, Zweli Mkhize, said they had verified the effectiveness of the vaccine with a new strain in South Africa and found that the vaccine provided only "minimal protection" against mild and moderate cases, but that 90 percent of cases in South Africa were currently caused by new variants.

In addition, AstraZeneca’s high rate of side effects has raised concerns. 


On 19 February, 194 employees of a German hospital were vaccinated, 30 had high fevers, headaches and obvious side effects, and France received a total of 149 reports of severe side effects between 6 and 10 February, with an average age of 34, the National Drug Safety Agency (ANSM)said in a report Also on March 2, South Korea received 51 reports of adverse reactions,3 people with breathing difficulties and red rashes, and more than 3,600 side effects reported in 10 days.

Perhaps that is why officials point out that in continental Europe, when AstraZeneca vaccines are available, no reservations are made and vaccination centers are empty. Two regions in Sweden have temporarily suspended AstraZeneca vaccinations, and hundreds of thousands of doses of AstraZeneca have not been used in Germany. In general, public support for vaccines has become a problem. If there is a problem with the COVID vaccine, trust in other life-saving vaccines will be further eroded, and if vaccination rates fall, more people, especially children, will be at risk.  For vaccine manufacturers, life should be a risk that cannot be risked.

If a vaccine may only bring limited benefits to those most in need and may put vulnerable people at risk, it is certainly not the best option.

Declaração: Este artigo é reproduzido em outras mídias. O objetivo da reimpressão é transmitir mais informações. Isso não significa que este site concorda com suas opiniões e é responsável por sua autenticidade, e não tem nenhuma responsabilidade legal. Todos os recursos deste site são coletados na Internet. O objetivo do compartilhamento é apenas para o aprendizado e a referência de todos. Se houver violação de direitos autorais ou propriedade intelectual, deixe uma mensagem.

Mais recentes

  • Inauguração da Exposição Digital do Comércio Internacional China-América Latina de 2022

    No dia 20 de Setembro de 2022 foi inaugurada a Exposição Digital de Comércio Internacional China-América Latina na plataforma B2B A exposição é organizada pelo China Council for the Promotion of International Trade e co-realizada pela China Chamber of International Commerce e pela Jiangsu United Asia International Exhibition Co., Ltd. Esta exposição digital contará com um modelo inovador de 10 dias de exposição online + 30 dias de comércio online + 365 dias de exposição online. Tem por objectivo aprofundar a cooperação em campos tradicionais, expandir a cooperação em indús
  • GEM, a Leading Green Enterprise in China, will land on the Swiss Exchange

    GEM (stock code: 002340), a company listed on the Shenzhen Stock Exchange, announced that on June 22, 2022, that the China Securities Regulatory Commission (CSRC) gave its approval for the company to issue global depository receipts (GDR) and to be listed on the Swiss Exchange (SIX). On July 20, 2022, SIX approved GEM to issue GDR and to be listed on the SIX. So far, the path of GEM issuing GDR and going public on the SIX have been unimpeded.
  • Lançado oficialmente! “O 1º Pod Mod Descartável” ZOVOO DRAGBAR R6000 revela o mistério

    O lançamento do novo produto ZOVOO 2022 foi transmitido em directo para todo o mundo no dia 29 de Junho. A ZOVOO lançou 4 novos produtos revolucionários, a tecnologia de núcleo cerâmico GENE TREE Special Edition, e o desempenho de topo no campo da atomização electrónica. O excelente desempenho da ZOVOO conquistou todos de novo, atraindo a atenção de numerosos meios de comunicação, parceiros e fãs globais.
  • Desempenho de Topo!O Lançamento Global Online ZOVOO 2022 será realizado em breve

    O Lançamento Global Online de Produtos ZOVOO 2022 terá início às 22 horas (GMT+8) do dia 29 de Junho. A ZOVOO vai atingir um novo pico no campo do vaping com a nova experiência que os produtos de vaping descartáveis ultrapassam de forma abrangente, e definir um novo padrão de vapes descartáveis na nova era.
  • Alcançando novos patamares, a VOOPOO ganhou 3 prémios na SÉTIMA CERIMÓNIA ANNUAL DOS PRÉMIOS VAPOUROUND

    No dia 27 de Maio, hora de Birmingham, realizou-se no The National Conference Centre em Birmingham, Reino Unido, a 7ª cerimónia de entrega de prémios realizada pela Vapouround, uma organização de meios de comunicação social com autoridade em matéria de atomização electrónica. A VOOPOO, a marca líder na indústria da atomização electrónica, foi mais uma vez amplamente reconhecida pelos organizadores e por muitos utilizadores, e os seus produtos ganharam três prémios, Melhor Sistema de Pod, Melhor Mod, e Melhor Fabrico.
  • Exposição On-line (Oriente Médio e Europa) realizada com sucesso pela Zhejiang Indústria e Comércio de Móveis Famosos

    Patrocinado pela Zhejiang CCPIT e organizado pela Yiwu Boyu Exhibition Service Co., a exposição 2022 on-line (Oriente Médio e Europa) da Zhejiang Indústria e Comércio de Móveis Famosos, foi realizada com sucesso com fechamento em 21 de maio, totalizando 1.8 milhão de dólares americanos em negócios realizados.
  • “Meta One” Will Launch Mobile App Soon!

    Metaverse Federation and Metaverse Federation University and the Meta Time together announced that “Meta One” will officially launch for mobile App on May 20th, 2022!
  • Aviso de exposição | A famosa exposição na industria de móveis de Zhejiang ( Europa central e oriental ) feira on-line com início dia 17 até 21 de maio.

    Como suporte às empresas de móveis de Zhejiang e com o intuito de explorar o mercado internacional, o Conselho para a promoção do Comercio Internacional de Zhejiang irá apresentar à famosa exposição da indústria de móveis de Zhejiang(Europa central e oriental) 2022 de 17 até 21 de maio para ajudar as empresas expandir à participação no mercado da Europa central e oriental, através do marketing digital.
  • A história da VOOPOO e Spark Your Life

    Em 11 de abril de 2022, a VOOPOO lançou seu produto anual, o ARGUS GT 2. Com sua saída constante de alta potência de 200W, classificação IP68 e design de cratera vulcânica, o ARGUS GT 2 traz uma experiência mais inovadora para os usuários de todo o mundo.


Back to top
© Copyright 2006-2020      Contate-nos   SiteMap